Dyax signs distribution contract with taiba for Kalbitor in Middle East
Taiba expects to launch Kalbitor in 2012. The profits on Kalbitor sales within the licensed territory will be shared by Dyax and taiba. Dyax president and chief executive
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
The company manufactures a recombinant mammalian cell produced third-generation Sci-B-Vac in its biologics manufacturing facility in Rehovot, Israel. The multiple clinical studies conducted on Sci-B-Vac have demonstrated that